Prostate cancer is lethal when tumors evolve to activate androgen receptor signaling, which circumvents ligand-deprivation therapy. In this issue of Cancer Cell, Groner et al. show that histone reader and transcription co-regulator TRIM24 occupies a central role in this evolution, nominating inhibitors of TRIM24’s bromodomain as a new therapeutic avenue.
Patel, L. R., & Barton, M. C. (2016, June 13). TRIM-ing Ligand Dependence in Castration-Resistant Prostate Cancer. Cancer Cell. Cell Press. https://doi.org/10.1016/j.ccell.2016.05.014